在法国前性NS-Park队列中使用阿曼塔丁
Margherita Fabbri1,2,3, Vanessa Rousseau4, Jean-Christophe Corvol5,6,7
1Department of Clinical Pharmacology and Neurosciences, Clinical Investigation Center CIC1436, Toulouse Parkinson Expert Centre, Toulouse NeuroToul Center of Excellence in Neurodegeneration (COEN), University of Toulouse 3, CHU of Toulouse, INSERM, Toulouse, France. margheritafabbrimd@gmail.com.
Journal of neural transmission (Vienna, Austria : 1996)
|April 5, 2024
概括
大约12%的帕金森病患者使用阿曼塔丁,特别是那些症状更严重的年轻人. 阿曼塔丁的启动有助于减少帕金森病患者的Levodopa诱导的动力障碍和运动波动.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 立即释放的阿曼塔丁已被批准用于帕金森病 (PD) 和通常用于levodopa诱导的运动障碍症 (LIDs).
- 阿曼塔丁的使用模式因国家和PD阶段而异.
- 未来的NS-Park队列研究涉及来自26个法国PD专家中心的PD患者.
研究的目的:
- 评估阿曼塔丁在帕金森病 (PD) 患者中使用的流行率.
- 确定与阿曼塔丁启动相关的因素及其对运动和非运动症状的影响.
- 评估阿曼塔丁对莱沃多巴诱导的运动障碍 (LIDs),运动波动 (MFs),冷漠,冲动控制障碍和步态结 (FoG) 的影响.
主要方法:
- 横截面分析比较了阿曼塔丁使用者与非使用者的临床特征.
- 纵向分析确定了与阿曼塔丁启动相关的因素.
- 纵向分析评估了阿曼塔丁对LID,MF,冷漠,冲动控制障碍和FoG的影响.
主要成果:
- 阿曼塔丁使用率为12.6%,使用者年轻,PD持续时间较长,利沃多巴每日相当剂量 (LEDD) 更高,症状更严重.
- 与阿曼塔丁启动相关的因素包括年轻年龄,更长的PD持续时间,频繁的LID,MF,FoG,更高的LEDD和更好的认知功能.
- 与从未使用阿曼塔丁的用户相比,新的阿曼塔丁用户在LID和MF中表现出更大的改善.
结论:
- 法国NS-Park队列中大约12%的PD患者使用阿曼塔丁,主要是患有更严重疾病的年轻患者.
- 开始服用阿曼塔丁与减少勒沃多巴诱导的运动障碍 (LIDs) 和运动波动 (MFs) 有关.
相关概念视频
01:24Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
01:22Alzheimer's Disease: Treatment
184
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184
01:15Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
01:23Antidepressant Drugs: MAOIs and Other Agents
228
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
228